All NewsCompany NewsTechnology

NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research

May 3, 2023
Houston, May 3, 2023 - NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene…
All NewsCompany NewsTechnology

Bio-Rad and NuProbe Enter into an Exclusive Licensing Agreement for Digital PCR Applications

November 4, 2022
HERCULES, Calif. and Houston, Texas— November 4, 2022 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in…
All NewsCompany NewsStrategic Collaborations

NuProbe Closes $50M in New Fundraising

June 2, 2022
Houston, TX, Jun 02, 2022 -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…
All NewsTechnology

NuProbe Published Method for Designing Highly Multiplex PCR Primer Sets

April 19, 2022
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
All NewsTechnology

NuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA

April 5, 2022
The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1%…
All NewsTechnology

NuProbe Technology Showcases Quantitative PCR for Simultaneous Enrichment and Identification of Multiple Rare Variants below 0.1% VAF

January 18, 2022
NuProbe published research demonstrating new technology to qualitatively and quantitively detect multiple low-frequency variants in one quantitative PCR (qPCR) reaction.
All NewsTechnology

NuProbe Technology Enables Accurate Quantitation of Mutations Below 0.01% VAF using Low-Depth Sequencing

October 21, 2021
By integrating molecular barcoding technology with the Blocker Displacement Amplification (BDA) allele enrichment, the team invented the new quantitative BDA (QBDA)…
All NewsStrategic Collaborations

C2i Genomics Expands AI-Powered Cancer Detection and Monitoring Capabilities in US and China Through Partnership with NuProbe

October 13, 2021
The deal will combine C2i's AI-driven cancer intelligence platform with NuProbe's advanced sequencing technology to power pharma and diagnostic services.
All NewsTechnology

NuProbe technology Enables Rapid Ultrasensitive Mutation Detection on Nanopore Platforms

September 7, 2021
OCEANS enables rapid, accurate, and affordable detection of somatic mutations as low as 0.05% VAF. This novel research will facilitate…
All NewsStrategic Collaborations

NuProbe Global and Bionano to Co-Develop Products in Reproductive Health and Oncology Testing

September 1, 2021
NuProbe will integrate QASeq and BDA technologies with Bionano's Saphyr system for research and product development in the fields of…